LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer - Business Wire

LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer  Business Wire

AstraZeneca and Merck's LYNPARZA Is the First PARP Inhibitor to Demonstrate Benefit in gBRCAm Metastatic Pancreatic Cancer in a Phase 3 Trial. February ...



Comments

Popular posts from this blog

His Apple Watch warned of an irregular heart rate. Turns out he was having a heart attack | Globalnews.ca - Global News Toronto

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more